πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 41 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9676840

Anti-CD100 neutralizing antibodies and methods of using the same

VACCINEX, INC. Β· Granted Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9603922

Modulation of NKT cell activity with antigen-loaded CD1d molecules

VACCINEX, INC. Β· Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9605055

Anti-CD100 antibodies and methods of using the same

VACCINEX, INC. Β· Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9598495

Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

VACCINEX, INC. Β· Granted Tue Mar 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9512224

Use of semaphorin-4D binding molecules for treatment of atherosclerosis

VACCINEX, INC. Β· Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9382327

Anti-CD20 antibodies and methods of use

VACCINEX, INC. Β· Granted Tue Jul 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9371352

Modified glycolipids and methods of making and using the same

VACCINEX, INC. Β· Granted Tue Jun 21 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9249227

Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

VACCINEX, INC. Β· Granted Tue Feb 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9243068

Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases

VACCINEX, INC. Β· Granted Tue Jan 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8834883

Anti-VEGF antibodies and uses thereof

VACCINEX, INC. Β· Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8816058

Polynucleotides encoding anti-CD100 antibodies or antigen-binding fragments thereof

VACCINEX, INC. Β· Granted Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8790652

Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules

VACCINEX, INC. Β· Granted Tue Jul 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8637026

Anti-C35 antibody combination therapies and methods

VACCINEX, INC. Β· Granted Tue Jan 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8496938

Anti-CD100 neutralizing neutralizing antibodies and methods of using the same

VACCINEX, INC. Β· Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7919594

Human anti-CD100 antibodies

VACCINEX, INC. Β· Granted Tue Apr 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7919095

Anti-IL-6 monoclonal antibodies

VACCINEX, INC. Β· Granted Tue Apr 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7807168

Selection of human TNFΞ± specific antibodies

VACCINEX, INC. Β· Granted Tue Oct 05 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted